Loading
Seventy-four heavily pre-treated patients whose bowel cancers had lost DNA mismatch repair were given nivolumab; nearly a third responded and most of those responses were still going a year later.
In this multicentre, open-label, phase 2 trial, adults with histologically confirmed mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer received nivolumab, with investigator-assessed objective response by RECIST 1.1 as the primary endpoint. Of the 74 patients enrolled between March 2014 and March 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12.0 months, 23 patients (31.1%) achieved an objective response and 51 (69%) had disease control for 12 weeks or longer. Median duration of response was not reached, all responders were alive, and 8 had responses lasting 12 months or longer. The most common grade 3 or 4 drug-related adverse events were raised lipase (8%) and amylase (3%), and none of the 23 deaths during the study was considered treatment related.
It gave the second PD-1 antibody a colorectal indication in mismatch repair deficient disease and, with the ipilimumab cohort that followed, set up CheckMate 8HW and the first-line combination.
Shares CheckMate 8HW, MSI and mismatch-repair testing, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing).
Shares Thierry André, MSI and mismatch-repair testing, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing).
Shares MSI and mismatch-repair testing, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2).
Shares CheckMate 8HW, MSI and mismatch-repair testing, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing).
Shares MSI and mismatch-repair testing, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2).
Shares MSI and mismatch-repair testing, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2).
Shares MSI and mismatch-repair testing, dMMR (mismatch repair deficiency by IHC), MSI-high (microsatellite instability by PCR or sequencing), Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2).
Shares Thierry André, CheckMate 8HW, Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).